K C Wilson1,2,3, M P Flood4,5,6, D Oh6, N Calvin6, M Michael7,6, R G Ramsay4,5, A G Heriot4,6. 1. Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Kasmira.wilson@petermac.org. 2. Differentiation and Transcription Laboratory, Sir Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Kasmira.wilson@petermac.org. 3. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Kasmira.wilson@petermac.org. 4. Department of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 5. Differentiation and Transcription Laboratory, Sir Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 6. Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. 7. Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Abstract
BACKGROUND: Limited therapy options exist for patients with treatment-refractory metastatic colorectal or anal cancers, prompting investigation into alternative therapies. Immunotherapy in the form of immune checkpoint blockade is one such emerging treatment that has demonstrated promising results in other tumour streams.x This review aims to assess the current use of immune checkpoint blockade in patients with lower gastrointestinal tumours. PATIENTS AND METHODS: Embase, Medline and Cochrane databases were searched for included studies. Clinical trials published in English and utilising immune checkpoint blockade for primary tumours situated in the lower gastrointestinal tract were included. Databases were searched for studies reporting on at least one of overall survival, progression-free survival or response to therapy. RESULTS: In total, 972 abstracts were screened, with 10 studies included in the final review. Eight trials (833 patients) assessed immune checkpoint blockade in the setting of colorectal cancers. These included pembrolizumab, nivolumab, durvalumab, atezolizumab, tremelimumab and ipilimumab. A total of 20 patients across all studies achieved a complete response, and 111 patients achieved a partial response to treatment. Two trials (62 patients) assessed immune checkpoint blockade in anal cancer, utilising nivolumab and pembrolizumab. Two patients across both studies achieved a complete response, and 11 patients achieved a partial response. CONCLUSIONS: A number of patients with advanced lower gastrointestinal tumours achieved a complete response to treatment for what would otherwise be considered palliative disease. Presented data have highlighted that particular patients may benefit from first-line or combination immunotherapy, and thus, further investigation is warranted to individualise treatment.
BACKGROUND: Limited therapy options exist for patients with treatment-refractory metastatic colorectal or anal cancers, prompting investigation into alternative therapies. Immunotherapy in the form of immune checkpoint blockade is one such emerging treatment that has demonstrated promising results in other tumour streams.x This review aims to assess the current use of immune checkpoint blockade in patients with lower gastrointestinal tumours. PATIENTS AND METHODS: Embase, Medline and Cochrane databases were searched for included studies. Clinical trials published in English and utilising immune checkpoint blockade for primary tumours situated in the lower gastrointestinal tract were included. Databases were searched for studies reporting on at least one of overall survival, progression-free survival or response to therapy. RESULTS: In total, 972 abstracts were screened, with 10 studies included in the final review. Eight trials (833 patients) assessed immune checkpoint blockade in the setting of colorectal cancers. These included pembrolizumab, nivolumab, durvalumab, atezolizumab, tremelimumab and ipilimumab. A total of 20 patients across all studies achieved a complete response, and 111 patients achieved a partial response to treatment. Two trials (62 patients) assessed immune checkpoint blockade in anal cancer, utilising nivolumab and pembrolizumab. Two patients across both studies achieved a complete response, and 11 patients achieved a partial response. CONCLUSIONS: A number of patients with advanced lower gastrointestinal tumours achieved a complete response to treatment for what would otherwise be considered palliative disease. Presented data have highlighted that particular patients may benefit from first-line or combination immunotherapy, and thus, further investigation is warranted to individualise treatment.
Authors: Rebecca L Siegel; Kimberly D Miller; Ann Goding Sauer; Stacey A Fedewa; Lynn F Butterly; Joseph C Anderson; Andrea Cercek; Robert A Smith; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2020-03-05 Impact factor: 508.702
Authors: Y Alamri; P Buchwald; L Dixon; B Dobbs; T Eglinton; J McCormick; C Wakeman; F A Frizelle Journal: Eur J Surg Oncol Date: 2016-05-25 Impact factor: 4.424
Authors: Bernhard Fankhaenel; Joerg Zimmer; Dorothea Bleyl; Eric Puffer; Andreas Schreiber; Thomas Kittner; Helmut Witzigmann; Sigmar Stelzner Journal: Int J Colorectal Dis Date: 2019-10-22 Impact factor: 2.571
Authors: K Tamas; A M E Walenkamp; E G E de Vries; M A T M van Vugt; R G Beets-Tan; B van Etten; D J A de Groot; G A P Hospers Journal: Cancer Treat Rev Date: 2015-06-28 Impact factor: 12.111
Authors: Michael J Overman; Sara Lonardi; Ka Yeung Mark Wong; Heinz-Josef Lenz; Fabio Gelsomino; Massimo Aglietta; Michael A Morse; Eric Van Cutsem; Ray McDermott; Andrew Hill; Michael B Sawyer; Alain Hendlisz; Bart Neyns; Magali Svrcek; Rebecca A Moss; Jean-Marie Ledeine; Z Alexander Cao; Shital Kamble; Scott Kopetz; Thierry André Journal: J Clin Oncol Date: 2018-01-20 Impact factor: 44.544
Authors: Cathy Eng; Tae Won Kim; Johanna Bendell; Guillem Argilés; Niall C Tebbutt; Maria Di Bartolomeo; Alfredo Falcone; Marwan Fakih; Mark Kozloff; Neil H Segal; Alberto Sobrero; Yibing Yan; Ilsung Chang; Anne Uyei; Louise Roberts; Fortunato Ciardiello Journal: Lancet Oncol Date: 2019-04-16 Impact factor: 41.316